Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

SARS-CoV-2-BA.4/5-adapted-bivalent-BNT162b2-vaccine ((bv)BNT), developed in response to the recent emergence of immune-evasive Omicron-variants, has been given to individuals who completed at least 2-doses of the monovalent-BNT162b2-vaccine ((mv)BNT). In the present cohort study, we evaluated neutra...

Descripción completa

Detalles Bibliográficos
Autores principales: Amano, Masayuki, Otsu, Sachiko, Uemura, Yukari, Ichikawa, Yasuko, Matsumoto, Shota, Higashi-Kuwata, Nobuyo, Matsushita, Shuzo, Shimada, Shinya, Mitsuya, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575932/
https://www.ncbi.nlm.nih.gov/pubmed/37833390
http://dx.doi.org/10.1038/s41598-023-44484-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575932/
https://www.ncbi.nlm.nih.gov/pubmed/37833390
http://dx.doi.org/10.1038/s41598-023-44484-x

Ejemplares similares